New Treatment Options against Carbapenem-Resistant Acinetobacter baumannii Infections

Burcu Isler, Yohei Doi, Robert A. Bonomo, David L. Paterson

研究成果: Article

19 引用 (Scopus)

抄録

Carbapenem-resistant Acinetobacter baumannii (CRAB) is a perilous nosocomial pathogen causing substantial morbidity and mortality. Current treatment options for CRAB are limited and suffer from pharmacokinetic limitations, such as high toxicity and low plasma levels. As a result, CRAB is declared as the top priority pathogen by the World Health Organization for the investment in new drugs. This urgent need for new therapies, in combination with faster FDA approval process, accelerated new drug development and placed several drug candidates in the pipeline. This article reviews available information about the new drugs and other therapeutic options focusing on agents in clinical or late-stage preclinical studies for the treatment of CRAB, and it evaluates their expected benefits and potential shortcomings.

元の言語English
ジャーナルAntimicrobial agents and chemotherapy
63
発行部数1
DOI
出版物ステータスPublished - 01-2019

Fingerprint

Acinetobacter Infections
Acinetobacter baumannii
Carbapenems
Pharmaceutical Preparations
Drug Approval
Pharmacokinetics
Morbidity
Mortality
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

これを引用

@article{9bd20cdfed584015a0e0f699baf14c4d,
title = "New Treatment Options against Carbapenem-Resistant Acinetobacter baumannii Infections",
abstract = "Carbapenem-resistant Acinetobacter baumannii (CRAB) is a perilous nosocomial pathogen causing substantial morbidity and mortality. Current treatment options for CRAB are limited and suffer from pharmacokinetic limitations, such as high toxicity and low plasma levels. As a result, CRAB is declared as the top priority pathogen by the World Health Organization for the investment in new drugs. This urgent need for new therapies, in combination with faster FDA approval process, accelerated new drug development and placed several drug candidates in the pipeline. This article reviews available information about the new drugs and other therapeutic options focusing on agents in clinical or late-stage preclinical studies for the treatment of CRAB, and it evaluates their expected benefits and potential shortcomings.",
author = "Burcu Isler and Yohei Doi and Bonomo, {Robert A.} and Paterson, {David L.}",
year = "2019",
month = "1",
doi = "10.1128/AAC.01110-18",
language = "English",
volume = "63",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "1",

}

New Treatment Options against Carbapenem-Resistant Acinetobacter baumannii Infections. / Isler, Burcu; Doi, Yohei; Bonomo, Robert A.; Paterson, David L.

:: Antimicrobial agents and chemotherapy, 巻 63, 番号 1, 01.2019.

研究成果: Article

TY - JOUR

T1 - New Treatment Options against Carbapenem-Resistant Acinetobacter baumannii Infections

AU - Isler, Burcu

AU - Doi, Yohei

AU - Bonomo, Robert A.

AU - Paterson, David L.

PY - 2019/1

Y1 - 2019/1

N2 - Carbapenem-resistant Acinetobacter baumannii (CRAB) is a perilous nosocomial pathogen causing substantial morbidity and mortality. Current treatment options for CRAB are limited and suffer from pharmacokinetic limitations, such as high toxicity and low plasma levels. As a result, CRAB is declared as the top priority pathogen by the World Health Organization for the investment in new drugs. This urgent need for new therapies, in combination with faster FDA approval process, accelerated new drug development and placed several drug candidates in the pipeline. This article reviews available information about the new drugs and other therapeutic options focusing on agents in clinical or late-stage preclinical studies for the treatment of CRAB, and it evaluates their expected benefits and potential shortcomings.

AB - Carbapenem-resistant Acinetobacter baumannii (CRAB) is a perilous nosocomial pathogen causing substantial morbidity and mortality. Current treatment options for CRAB are limited and suffer from pharmacokinetic limitations, such as high toxicity and low plasma levels. As a result, CRAB is declared as the top priority pathogen by the World Health Organization for the investment in new drugs. This urgent need for new therapies, in combination with faster FDA approval process, accelerated new drug development and placed several drug candidates in the pipeline. This article reviews available information about the new drugs and other therapeutic options focusing on agents in clinical or late-stage preclinical studies for the treatment of CRAB, and it evaluates their expected benefits and potential shortcomings.

UR - http://www.scopus.com/inward/record.url?scp=85058910098&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058910098&partnerID=8YFLogxK

U2 - 10.1128/AAC.01110-18

DO - 10.1128/AAC.01110-18

M3 - Article

C2 - 30323035

AN - SCOPUS:85058910098

VL - 63

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 1

ER -